Matteo Loverro

In this #IJGCconevrsations epidose, @pedroramirezMD discusses about real-word #PARPi maintenance and recurrence patterns with @MatteoLoverro and @annafagottimd @Unicatt Tune in now 🎧 bit.ly/3ENgwko @pedroramirezMD @HsuMd @JayrajAarthi @AndreFernandes2 @IGCSociety @ESGO_society @ENYGO_official @OncoAlert @IJGCfellows @GynMe4 @thomasbartlMD @kfischermd @claritasantia @stephjeangill @MMontesinos_Alb @braunchristian1 @mattmarchettiMD @yates_elisemann @jhgelissen

And that's a wrap!!! The last #IJGCClub of the year, with an incredible guest. 🔥 Thank you, Luis @lchiv4 for such a wonderful and insightful discussion. We had 82 attendees, one of our largest attendances for journal clubs! 🤩 Thanks to @IGCSociety and @ESGO_society for all the support, and to the best fellows for your wonderful questions. You can find the recording here 👉 bit.ly/4rZhL3x @pedroramirezMD @HsuMd @JayrajAarthi @AndreFernandes2 @ENYGO_official @OncoAlert @IJGCfellows @GynMe4 @MathildeDel2 @DrPervan @T_Meschini @moe_byrneMD @MatteoLoverro @CSabiniMD @ZaniruRaul

ℹ️ Join ENYGO next week for a Surgical Mentorship webinar on pelvic exenteration & reconstruction! This series of webinars enables young surgeons to share their accomplishments and discuss them with leading experts. 🙌 On October 30, we welcome: Experts 🔸Gwenael Ferron 🔸Vito Chiantera 🔸Nicolo Bizzarri Presenters 🔸Matteo Loverro 🔸Giuseppe Cucinella 🔸Martina Angeles Moderators 🔸Louisa Proppe 🔸Enrique Chacon

Join us #IJGCclub 📆16/10/2025 ⏰11am CDT/6pm CET Mark your calendars 📅 for an exciting #IJGCclub 💥 Endometrial carcinosarcoma without myoinvasion with Giuseppe Cucinella @Cucinella_G and Mario Leitao @leitaomd 💻 bit.ly/4jfSMEP @pedroramirezMD @HsuMd @JayrajAarthi @AndreFernandes2 @IGCSociety @ESGO_society @ENYGO_official @OncoAlert @IJGCfellows @GynMe4 @MathildeDel2 @DrPervan @T_Meschini @moe_byrneMD @MatteoLoverro @CSabiniMD @ZaniruRaul

#EditorsChoice #UterineLeiomyosarcoma is rare, aggressive, and hard to diagnose. Multidisciplinary care is key. 👉 Learn more in the latest review: bit.ly/4n1ydNY @gcarusomd @BoganiGiorgio @pedroramirezMD @HsuMd @JayrajAarthi @AndreFernandes2 @IGCSociety @ESGO_society @ENYGO_official @OncoAlert @IJGCfellows @GynMe4 @MathildeDel2 @DrPervan @T_Meschini @moe_byrneMD @MatteoLoverro @CSabiniMD @ZaniruRaul

🎙️ New #IJGCconversations! @pedroramirezMD talks with Tyler Hillman & Allison Lynn Brodsky about surgical approach in recurrent granulosa cell tumor. 🎧 Don’t miss this insightful discussion 👉 bit.ly/3KoXinq @HsuMd @JayrajAarthi @AndreFernandes2 @IGCSociety @ESGO_society @ENYGO_official @OncoAlert @IJGCfellows @GynMe4 @RParejaGineOnco @lchiv4 @annafagottimd @HousseinELHAJJ3 @AinhoaMada @MathildeDel2 @DrPervan @T_Meschini @moe_byrneMD @MatteoLoverro @CSabiniMD @ZaniruRaul #WeeklyPodcast #LeadArticle #IJGConline #Research #Prevention #Treatment #Diagnostic #GynCancer #GynOnc #WomenHealth #SoMe #SoMe4GynOnc

The OncoAlert WEEKLY RoundUp 🚨 Covering the TOP of the week Sept 5-11, 2025 REGISTER at OncoAlert360.com OR oncoalert.m-pages.com/nhMpwe… Discussing: ✅ EGFR+ #NSCLC : Amivantamab–Lazertinib vs Osimertinib🫁 Amivantamab–lazertinib boosts 3-year OS to 60% vs 51% in untreated EGFR+ NSCLC, but watch for higher grade ≥3 toxicities ⚠️ ✅ SCLC: Tarlatamab + PD-L1 Inhibitor Tarlatamab with PD-L1 therapy shows manageable toxicity and promising median OS of 25.3 months in extensive-stage #SCLC ✅ COCOON Trial: Skin Toxicity Prevention in EGFR+ Non Small Cell #LungCancer 🫁 Simple prophylactic dermatologic care cut grade ≥2 skin toxicity from 75% to 42% and improved QoL in patients on amivantamab-lazertinib ✨ ✅A-BRAVE: Adjuvant Avelumab in High-Risk #TNBC Avelumab didn’t improve DFS in high-risk early TNBC but hints at better overall survival, regardless of PD-L1 status 💡 ✅SONIA ctDNA🧬 Analysis: CDK4/6 Timing in Advanced #BreastCancer Pretreatment ctDNA predicts who benefits most from first-line CDK4/6 inhibitors in advanced ER+ HER2− breast cancer 🧪 ✅ Early Detection of Pancreatic Cancer via cfDNA🩸 Machine learning on cfDNA fragmentomics detects early-stage #PancreaticCancer with >90% accuracy ✅HCC: Epidemiology, Diagnosis & Treatment Hepatocellular carcinoma is rising due to non-viral causes; early detection and immunotherapy improve outcomes but gaps remain 🏥 #LiverCancer ✅Oligometastatic RCC: Radiotherapy☢️ Alone Metastasis-directed radiotherapy delayed systemic therapy nearly 3 years in oligometastatic RCC with minimal toxicity. #KidneyCancer ✅mCRPC: Pembrolizumab + Enzalutamide Adding pembrolizumab to enzalutamide didn’t improve survival but increased grade ≥3 toxicities in chemo-naive mCRPC ❌ #ProstateCancer ✅ PORTEC-3: Adjuvant Chemoradiotherapy in High-Risk #EndometrialCancer Chemoradiotherapy boosts 10-year OS to 74% vs 67% with greatest benefit in p53-abnormal tumors 💪 ✅🏥 Stage IV Endometrial Cancer: Surgery & Molecular Profiling Surgery improves survival over chemo alone, and molecular subtype guides prognosis in stage IV endometrial cancer 🔬 ✅ ICIs in Advanced #Sarcoma : IMPRESARC ICIs show modest efficacy overall, but select subtypes like ASPS, chordoma, SMARCA4-deficient, GIST, and NF1-mutated sarcomas get durable responses ✨ @VivekSubbiah @Latinamd @JadChahoud @Jaskirat__SR @LuisLara_M @StephenVLiu @RManochakian @MAWi1dgust @tuttsakhil @AnaVManana @APassaroMD @lungoncdoc @UOzkerim @DrRishabhOnco @M_Torasawa @chulkimMD @RenoHemonc @BZhangMD @BenWestphalen @PathologyPat @yymgcmd @ErikaHamilton9 @YAbdouMD @MamMa_mimumemo @LoiSher @AnisToumeh @ChadTangMD @changjeesuk1 @Sushilberiwal @_ShankarSiva @PavlosMsaouel @Sid423 @drskmishra1984 @urogomez_ @toddscarbrough @gusviani @bhavanaparikh1 @MatteoLoverro @leitaomd